This topic contains a solution. Click here to go to the answer

Author Question: Which of the following is not an area of ACAs Advocacy Competencies? A. Client/student B. ... (Read 101 times)

Chloeellawright

  • Hero Member
  • *****
  • Posts: 588
Which of the following is not an area of ACAs Advocacy Competencies?
 
  A. Client/student
  B. School/community
  C. Public arena
  D. World arena

Question 2

The best definition of empathy is
 
  a. to feel pity for the client.
  b. to tell the client that you know what he or she is feeling.
  c. to sense the private world of the client as if it were your own.
  d. to feel sympathy.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Missbam101

  • Sr. Member
  • ****
  • Posts: 341
Answer to Question 1

D

Answer to Question 2

c




Chloeellawright

  • Member
  • Posts: 588
Reply 2 on: Jul 30, 2018
Excellent


hollysheppard095

  • Member
  • Posts: 339
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

Human neurons are so small that they require a microscope in order to be seen. However, some neurons can be up to 3 feet long, such as those that extend from the spinal cord to the toes.

Did you know?

Signs and symptoms of a drug overdose include losing consciousness, fever or sweating, breathing problems, abnormal pulse, and changes in skin color.

Did you know?

The cure for trichomoniasis is easy as long as the patient does not drink alcoholic beverages for 24 hours. Just a single dose of medication is needed to rid the body of the disease. However, without proper precautions, an individual may contract the disease repeatedly. In fact, most people develop trichomoniasis again within three months of their last treatment.

Did you know?

Patients should never assume they are being given the appropriate drugs. They should make sure they know which drugs are being prescribed, and always double-check that the drugs received match the prescription.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library